How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Phytopathological Disease Diagnostic Kit Market
- By Technology: Polymerase Chain Reaction (PCR) Kits, Enzyme-Linked Immunosorbent Assay (ELISA) Kits, Lateral Flow Assay Kits, DNA Microarray Kits, Loop-Mediated Isothermal Amplification (LAMP) Kits
- By Target Pathogen Type: Fungal Disease Diagnostic Kits, Bacterial Disease Diagnostic Kits, Viral Disease Diagnostic Kits, Nematode Disease Diagnostic Kits, Phytoplasma Disease Diagnostic Kits
- By End User: Agricultural Research Institutes, Commercial Plantations, Seed Companies, Plant Clinics and Diagnostic Laboratories, Government Agricultural Departments
- By Sample Type: Leaf Tissue Kits, Soil Sample Kits, Seed Sample Kits, Sap Sample Kits, Root Tissue Kits
- By Application: Field Testing Kits, Laboratory Testing Kits, Greenhouse Disease Monitoring Kits, Post-Harvest Disease Detection Kits
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Polymerase Chain Reaction (PCR) Kits leads By Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Phytopathological Disease Diagnostic Kit Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Technology 5
Target Pathogen Type 5
End User 5
Sample Type 5
Application 4
Companies profiled
Thermo Fisher Scientific
Agdia Inc.
Neogen Corporation
Bioreba AG
LGC Limited
Eurofins Scientific
Merck KGaA (MilliporeSigma)
QIAGEN N.V.
BASF SE
Syngenta AG
DuPont de Nemours Inc.
Bio-Rad Laboratories Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Agdia Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Neogen Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bioreba AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →LGC Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Merck KGaA (MilliporeSigma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →QIAGEN N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →BASF SE
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Syngenta AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →DuPont de Nemours Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bio-Rad Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Phytodiagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Moleculera Labs
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Envirologix
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,835M by 2033 · 10.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Polymerase Chain Reaction (PCR) Kits51.5
- Enzyme-Linked Immunosorbent Assay (ELISA) Kits12.3
- Lateral Flow Assay Kits10.4
- DNA Microarray Kits15.7
- Loop-Mediated Isothermal Amplification (LAMP) Kits10.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$590.3M → $1,141M · 8.6%
Europe$411.4M → $931.9M · 10.8%
Asia Pacific$375.7M → $862.5M · 10.9%
Latin America$232.5M → $479.5M · 9.5%
Middle East and Africa$178.9M → $368.4M · 9.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.962026
9.962027
9.972028
9.982029
10.002030
10.012031
10.032032
10.032033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific18.9
- Agdia Inc.16.0
- Neogen Corporation7.2
- Bioreba AG10.1
- LGC Limited10.3
- Eurofins Scientific9.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Technology23.0%
Target Pathogen Type10.6%
End User22.6%
Sample Type22.2%
Application21.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.2
- Europe24.6
- Asia Pacific22.8
- Latin America12.7
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 74 | 87 | 74 | 89 | 76 | 93 | 82 |
| Agdia Inc. | 68 | 86 | 74 | 69 | 80 | 89 | 78 |
| Neogen Corporation | 65 | 69 | 82 | 73 | 84 | 79 | 75 |
| Bioreba AG | 73 | 74 | 75 | 66 | 79 | 57 | 71 |
| LGC Limited | 51 | 62 | 57 | 61 | 53 | 63 | 58 |
| Eurofins Scientific | 59 | 47 | 48 | 62 | 60 | 48 | 54 |
| Merck KGaA (MilliporeSigma) | 65 | 61 | 60 | 61 | 49 | 49 | 58 |
| QIAGEN N.V. | 52 | 60 | 48 | 49 | 58 | 40 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Agdia Inc.
- Neogen Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Agdia Inc. | − | ✓ | ✓ | ◐ | ◐ | ✓ |
| Neogen Corporation | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Bioreba AG | ✓ | ◐ | − | ◐ | ◐ | − |
| LGC Limited | − | ◐ | ◐ | − | ◐ | − |
| Eurofins Scientific | − | ◐ | ◐ | ◐ | − | ◐ |
| Merck KGaA (MilliporeSigma) | ◐ | − | ◐ | ◐ | − | − |
| QIAGEN N.V. | − | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific82
2Agdia Inc.78
3Neogen Corporation75
4Bioreba AG71
5LGC Limited58
6Merck KGaA (MilliporeSigma)58
7Eurofins Scientific54
8QIAGEN N.V.51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificAgdia Inc.
Challenger2
Strong scale, closing on the leaders.
Neogen CorporationBioreba AG
Contender2
Focused players with pockets of strength.
LGC LimitedMerck KGaA (MilliporeSigma)
Niche2
Specialists in a single segment or region.
Eurofins ScientificQIAGEN N.V.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technology in North America, then scale across Phytopathological Disease Diagnostic Kit Market — a $214M beachhead inside a $3.48B market.
Beachhead (SOM)$214Mobtainable near-term
Serviceable (SAM)$1.44Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Polymerase Chain Reaction (PCR) Kits
Best fit — highest urgency & budget in Technology.
Economic buyer76 fit
Enzyme-Linked Immunosorbent Assay (ELISA) Kits
Strong fit — clear ROI and a fast path to value.
End user69 fit
Lateral Flow Assay Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Pathogen Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Phytopathological Disease Diagnostic Kit Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified23%
Evaluation15%
Closed-won8%
$16.5KCAC
$79KLTV
4.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Phytopathological Disease Diagnostic Kit Market is a durable-growth opportunity — $1.31B by 2033, compounding at 7.0%.
TAM · 2025$757Mtoday
TAM · 2033$1.31Bforecast
CAGR7.0%2027–2033
Cumulative$9.08Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.31BTotal addressable market
SAM$544MServiceable available market
SOM$100MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.0% CAGR
Demand compounds through 2033, outpacing GDP across Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.31BLarge & growingTAM by 2033 at 7.0% CAGR
$544MServiceable nowreachable with today’s model
$100MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.02BBear4.6% CAGR
$1.31BBase7.0% CAGR
$1.67BBull9.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Pathogen Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Phytopathological Disease Diagnostic Kit Market — a $9.35B market by 2033. Plan: grow share from 10.5% to 16.8%.
Market size · 2033$9.35Btotal addressable
Market CAGR10.6%2027–2033
Target share16.8%from 10.5% today
Revenue ambition$1.57Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.5% | 16.8% | On track |
| Revenue | $939M | $1.57B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.5% | 42.5% | On track |
| Customer retention | 86.9% | 96.3% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Pathogen Type capability
A defensible second engine — invest in Target Pathogen Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Pathogen Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $208M capacity & capability investment
- Greenlight bolt-on M&A in Target Pathogen Type
- Authorise North America expansion plan
- Fund R&D program for Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Phytopathological Disease Diagnostic Kit Market conversation — a $7.05B market you can size, segment and defend in minutes.
Market size · 2033$7.05Btotal opportunity
Growth11.1%CAGR to 2033
Addressable buyers1,352+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology
Goal Grow share in Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 3 mopayback period
$79K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Thermo Fisher ScientificAgdia Inc.Neogen CorporationBioreba AGLGC LimitedEurofins ScientificMerck KGaA (MilliporeSigma)QIAGEN N.V.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Phytopathological Disease Diagnostic Kit Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Phytopathological Disease Diagnostic Kit Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Phytomenadione Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportPhytomenadione API Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportPhytohemagglutinin (PHA) Market
Market size, share, segmentation and regional forecast.
$422M market · 2025 base year
View reportPhytohemagglutinin Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportPhysostigmine Market
Market size, share, segmentation and regional forecast.
$849M market · 2025 base year
View reportPhysiotherapy Supplies Market
Market size, share, segmentation and regional forecast.
$895M market · 2025 base year
View reportPhysiotherapy Services Market
Physiotherapy Services Market is valued at USD 58.74 Billion in 2025 and is expected to reach U…
$58.7B market · 2025 base year
View reportPhysiotherapy Laser Wrist Watch Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportPhysiotherapy Heating Compress Equipment Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportPhysiotherapy Electrodes Market
Market size, share, segmentation and regional forecast.
$820M market · 2025 base year
View reportPhysiotherapy Couches Market
Market size, share, segmentation and regional forecast.
$736M market · 2025 base year
View reportPhysiotherapy Clinics Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.